Laboratorio Farmaceutico Erfo SpA is an Italy-based pharmaceutical company primarily engaged in the nutraceutical sector. The Company specializes in the production of nutritional supplements, that thanks to research and development carried out internally and in collaboration with the University Campus Bio-Medico of Rome and the University of Messina provides products with a scientific value in different therapeutic areas. The Company operates globally.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
12/26/12	1.100 €	+0.92%	35,000
11/26/11	1.090 €	-0.46%	25,000
10/26/10	1.095 €	0.00%	0
09/26/09	1.095 €	0.00%	11,000
08/26/08	1.095 €	-0.45%	21,000

Real-time Borsa Italiana

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Real-time Borsa Italiana Other stock markets 07:37:51 12/06/2026 pm IST			5-day change	1st Jan Change
1.100 ^EUR	+0.92%		0.00%	-25.17%

04/06	Equities trend higher; banks lead gains on the MIB	AN
22/05	European markets rebound; STM and Stellantis lead gains	AN

Market Cap	92.87L 1.07Cr 85.6L 80.21L 1.5Cr 102.47Cr 1.53Cr 10Cr 3.95Cr 49Cr 4.02Cr 3.93Cr 171.74Cr	P/E Ratio 2024	30.8x	P/E Ratio 2025	17x
Enterprise Value	95.82L 1.1Cr 88.33L 82.76L 1.55Cr 105.73Cr 1.58Cr 11Cr 4.08Cr 51Cr 4.15Cr 4.06Cr 177.2Cr	EV / Sales 2024	1.79x	EV / Sales 2025	1.32x
Free-Float	18.98%	Yield 2024 *	-	Yield 2025	-

04/06	Equities trend higher; banks lead gains on the MIB	AN
22/05	European markets rebound; STM and Stellantis lead gains	AN
21/05	Laboratorio Farmaceutico Erfo reports stable first-quarter revenue year-on-year	AN
21/05	Laboratorio Farmaceutico Erfo Q1 EBITDA adj. EUR 0.5 mln	RE
21/05	European markets set for lower open; focus on manufacturing PMIs	AN
20/04	Brent rebounds; futures signal risk-off sentiment	AN
17/04	Greenlight on Hormuz sparks global equity rally	AN
13/04	Laboratorio Farmaceutico Erfo S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/03	Laboratorio Farmaceutico Erfo posts triple-digit profit growth in 2025	AN
06/03	IG Futures Point to Higher European Markets	AN
05/03	US-Iran Conflict Fuels Commodity Rally; Mib Slides	AN
05/03	Active Markets; Traders Unconvinced by Nexi	AN
23/02	Europe Expected to Open Lower Amid US Tariff Uncertainty	AN

09/04	Laboratorio Farmaceutico Erfo S p A : Investor Presentation Erfo SpA FY2025 (ENG)	PU
21/25/21	Laboratorio Farmaceutico Erfo S p A : 2025 10 20-ERFO-NextGEMS	PU
29/25/29	Laboratorio Farmaceutico Erfo S p A : 2025 08 28 ERFO - Press release KPI 1H 2025	PU
04/25/04	Laboratorio Farmaceutico Erfo S p A : KT Erfo 1Q25 Final	PU
19/25/19	Laboratorio Farmaceutico Erfo S p A : KT Erfo FY24 Final	PU

Laboratorio Farmaceutico Erfo S.p.A. Share Price

Stocks

ERFO

IT0005497885

Pharmaceuticals

Valuation: Laboratorio Farmaceutico Erfo S.p.A.

Chart: Laboratorio Farmaceutico Erfo S.p.A.

Latest news : Laboratorio Farmaceutico Erfo S.p.A.

Press Releases: Laboratorio Farmaceutico Erfo S.p.A.

News in other languages: Laboratorio Farmaceutico Erfo S.p.A.

Quotes and Performance

Course Extremes

Managers and Directors: Laboratorio Farmaceutico Erfo S.p.A.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

04/06	Borse rialziste; bene i bancari sul MIB
22/05	Tornano gli acquisti in Europa; su STM e Stellantis
21/05	Laboratorio Farmaceutico Erfo chiude trimestre stabile su base annua
21/05	Laboratorio Farmaceutico Erfo S p A : 2026 05 21 ERFO - CS Dati gestionali Q1 2026 ITA-ENG
21/05	Europee attese giù; focus su PMI manifatturiero

1 day	+0.92%
Current month	+0.92%
1 month	-2.22%
3 months	-5.17%
6 months	-26.42%
Current year	-25.17%

1 week	1.07	1.11
1 month	1.06	1.18
Current year	1.01	1.6
1 year	1.01	1.8
3 years	0.88	1.8
5 years	0.88	3.3
10 years	0.88	3.3

Manager	Title	Age	Since
Alessandro Cutè CEO	Chief Executive Officer	55	01/01/2013
Daniele Travisano DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Alessandro Cutè CHM	Chairman	55	01/01/2013
Flavio Corpina BRD	Director/Board Member	47	01/01/2017
Fabio Giuffre BRD	Director/Board Member	45	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/12	Alessandro Cutè	Sell	Chief Executive Officer	3,22,000	3.5778%
16/12	Alessandro Cutè	Sell	Chief Executive Officer	9,68,000	10.7556%
29/22/29	Alessandro Cutè	Others	Chief Executive Officer	3,00,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LABORATORIO FARMACEUTICO ERFO S.P.A.	+0.92%	0.00%	-8.71%	-6.78%	1.07Cr
ELI LILLY AND COMPANY	-1.10%	+1.58%	+41.54%	+158.09%	1,03500Cr
JOHNSON & JOHNSON	+0.44%	+2.86%	+52.83%	+49.74%	57TCr
ABBVIE INC.	-0.07%	-1.09%	+16.81%	+63.19%	40TCr
ROCHE HOLDING AG	+0.58%	+0.77%	+21.19%	+15.95%	32TCr
ASTRAZENECA PLC	-0.77%	-2.97%	+21.91%	+13.66%	28TCr
NOVARTIS AG	+0.67%	+3.80%	+24.87%	+34.81%	28TCr
NOVO NORDISK A/S	+1.66%	+5.61%	-44.67%	-47.49%	19TCr
AMGEN INC.	+0.48%	+1.88%	+19.80%	+63.86%	19TCr
GILEAD SCIENCES, INC.	-0.88%	-3.11%	+11.69%	+60.73%	16TCr
Average	+0.17%	+1.07%	+15.73%	+40.58%	34.3TCr
Weighted average by Cap.	-0.14%	+2.39%	+28.26%	+72.45%

	2024	2025
Net sales	60.32L 69.51L 55.61L 52.1L 97.35L 67Cr 99.38L 6.63Cr 2.57Cr 32Cr 2.61Cr 2.55Cr 111.56Cr	97.32L 1.12Cr 89.7L 84.05L 1.57Cr 107.38Cr 1.6Cr 11Cr 4.14Cr 52Cr 4.21Cr 4.12Cr 179.97Cr
Net income	4L 4L 3L 3L 6L 3.89Cr 6L 38.8L 15.02L 1.88Cr 15.26L 14.93L 6.52Cr	7L 8L 7L 6L 11.89L 8.13Cr 12.14L 81.04L 31.37L 3.92Cr 31.88L 31.19L 14Cr
Net Debt	5.77T 6.65T 5.32T 4.98T 9.31T 6L 9.5T 63.41T 24.55T 3L 24.95T 24.41T 10.66L	3L 3L 3L 3L 5L 3.26Cr 5L 32.48L 12.58L 1.57Cr 12.78L 12.5L 5.46Cr